High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3

Exclusion Criteria

• •Pregnant or breastfeeding females.
• •Concurrent treatment with antineoplastic or immunomodulatory agents, including corticosteroids or radiation therapy over the last 6 months before starting the trial
• •Treatment with investigational drugs \< 6 weeks before starting the trial
• •Chronic liver disease other than hepatitis C.
• •Evidence of hepatocellular carcinoma.
• •Evidence of carcinoma hepatocellular
• •Decompensated liver disease
• •Baseline Neutrophil count \< 1500/cc; or Platelet count \< 90,000/cc
• •Baseline Hemoglobin \<12 g/dL in females o \<13 g/dL in males.
• •Increased risk of anemia(Eg, thalassemia, spherocytosis..).
• •Ischemic heart disease or cerebrovascular disease.
• •Serum creatinine \>1.5 times upper limit of normality.
• •History of severe psychiatric conditions (Major antidepressives or neuroleptic drugs required for major depression or psychosis), suicide attempts or psychiatric disability .
• •History of convulsive disorders.
• •Immunological conditions.
• •Chronic Obstructive Lung Disease with limited functionality
• •Severe heart disease or congestive cardiac insufficiency cardiopathy grave.
• •Advanced atherosclerosis
• •Solid organ or bone marrow transplant.